- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07676786
Euvolemia-Based Assessment of Pulmonary Hypertension in Stable Hemodialysis Patients (EU-PHASE-HD)
Prospective Observational Study on Predictors and Types of Pulmonary Hypertension in Euvolemic Patients With End-Stage Kidney Disease on Maintenance Hemodialysis
Pulmonary hypertension (PH) is a frequent and clinically significant complication in patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis (HD). However, PH assessment in this population is often confounded by volume overload, leading to potential overestimation and misclassification.
This prospective, multicenter observational study aims to evaluate the prevalence, phenotype, and predictors of PH in HD patients under standardized euvolemic conditions. A structured pretrial phase including volume assessment and correction will be performed prior to echocardiographic evaluation, which will be conducted after confirmation of euvolemia, post-hemodialysis or on the following day.
In participants with echocardiographic findings suggestive of PH, right heart catheterization may be performed when clinically indicated and after obtaining specific informed consent.
The study integrates clinical, biological, dialysis-related, and echocardiographic data to provide a comprehensive characterization of PH in a well-defined ESKD population.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Pulmonary hypertension (PH), defined as mean pulmonary arterial pressure (mPAP) >20 mmHg, is increasingly recognized in patients with chronic kidney disease and is particularly prevalent in those with ESKD on maintenance HD.
Despite its prognostic importance, PH remains under-recognized and insufficiently characterized in HD patients. A major limitation of prior studies is the lack of standardized assessment of volume status, which significantly influences pulmonary pressures.
This prospective, multicenter cohort study aims to address this gap by evaluating PH after rigorous volume optimization. The study includes:
- A pretrial volume assessment phase (3 consecutive HD sessions)
- A structured volume correction phase (if needed)
- A main study cohort including only euvolemic patients
- An exploratory subgroup of patients with persistent hypervolemia
Euvolemia is defined using a multimodal approach including clinical examination, bioimpedance spectroscopy, inferior vena cava (IVC) diameter, interdialytic weight gain, blood pressure stability, and lung ultrasound criteria.
The primary objective is to determine the prevalence of PH in euvolemic HD patients. Secondary objectives include characterization of PH phenotypes and identification of clinical, dialysis-related, and echocardiographic predictors.
Right heart catheterization (RHC) is not mandated for all participants. In patients with echocardiographic findings suggestive of PHafter confirmation of euvolemia, RHC may be performed when clinically indicated and separately consented. When available, invasive hemodynamic data will be used to confirm PH and refine phenotype classification.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Stefan N Lujinschi, MD, PhD candidate
- Número de telefone: +40728102643
- E-mail: stefanlujinschi@gmail.com
Locais de estudo
-
-
-
Bucharest, Romênia, 022328
- Fundeni Clinical Institute
-
Contato:
- Stefan N Lujinschi, MD, PhD candidate
- Número de telefone: +40728102643
- E-mail: stefanlujinschi@gmail.com
-
Investigador principal:
- Stefan N Lujinschi, MD, PhD candidate
-
Bucharest, Romênia, 022322
- Institute for Cardiovascular Diseases C.C. Iliescu
-
Contato:
- Georgiana Olaru, MD
- Número de telefone: +40767805197
- E-mail: dr.georgianaolaru@yahoo.com
-
Investigador principal:
- Georgiana Olaru, MD
-
Subinvestigador:
- Lucian M Predescu, Assist. Prof., MD, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Age ≥ 18 years.
- End-stage kidney disease on maintenance HD for ≥ 3 months.
- Stable clinical condition (no hospitalization in last 30 days).
- Able and willing to comply with study protocol.
- Provision of written informed consent
Exclusion Criteria:
- Moderate/severe left-sided valvular disease.
- Active pulmonary or cardiac decompensation.
- Persistent hypervolemia after completion of the volume assessment and correction phase
- Inability to undergo echocardiography or bioimpedance assessment.
- Acute infection or inflammatory condition at the time of enrollment.
- Inadequate echocardiographic window preventing reliable assessment
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Euvolemic Hemodialysis Cohort
Participants with end-stage kidney disease on maintenance hemodialysis undergo a structured volume assessment (including clinical assessment, bioimpedance spectroscopy, inferior vena cava measurement, lung ultrasound and echocardiography) and, if necessary, a volume optimization phase. The primary study cohort includes patients who meet predefined euvolemia criteria. An exploratory subgroup includes patients with persistent hypervolemia, analyzed separately. Additional invasive evaluation, including right heart catheterization, may be performed only when clinically indicated and is not assigned as a study intervention. |
Participants undergo structured clinical, echocardiographic, and volume status assessments, including bioimpedance spectroscopy, lung ultrasound and inferior vena cava evaluation. Volume optimization measures are applied as part of routine clinical care and are not assigned as experimental interventions. Right heart catheterization may be performed in selected patients when clinically indicated and after specific informed consent, and is not considered a study intervention. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Prevalence of Pulmonary Hypertension in Euvolemic Hemodialysis Patients
Prazo: At baseline echocardiographic evaluation after confirmation of euvolemia (within 1 week, post-hemodialysis or next day); in participants undergoing clinically indicated right heart catheterization, assessment may occur within 3 months
|
Pulmonary hypertension will be identified based on echocardiographic criteria (systolic pulmonary arterial pressure [sPAP] ≥40 mmHg) after confirmation of euvolemia.
In participants undergoing clinically indicated right heart catheterization, invasive hemodynamic data (mean pulmonary arterial pressure [mPAP] ≥20 mmHg) will be used for confirmation of pulmonary hypertension.
|
At baseline echocardiographic evaluation after confirmation of euvolemia (within 1 week, post-hemodialysis or next day); in participants undergoing clinically indicated right heart catheterization, assessment may occur within 3 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pulmonary Hypertension Phenotype Distribution
Prazo: At baseline echocardiography after euvolemia (within 1 week, post-hemodialysis or next day); in participants with clinically indicated right heart catheterization, assessment may occur within 3 months
|
Distribution of pulmonary hypertension phenotypes based on echocardiographic assessment in the overall cohort, with definitive classification based on right heart catheterization in patients undergoing clinically indicated invasive evaluation.
|
At baseline echocardiography after euvolemia (within 1 week, post-hemodialysis or next day); in participants with clinically indicated right heart catheterization, assessment may occur within 3 months
|
|
Predictors of Pulmonary Hypertension
Prazo: At baseline evaluation
|
Clinical, laboratory, dialysis-related, vascular access-related, and volume-related variables associated with the presence of pulmonary hypertension
|
At baseline evaluation
|
|
Association Between Vascular Access and Pulmonary Hypertension
Prazo: At baseline evaluation
|
Relationship between vascular access type and pulmonary hypertension parameters.
|
At baseline evaluation
|
|
Association Between Volume Status and Pulmonary Hypertension
Prazo: At baseline evaluation
|
Association between bioimpedance, inferior vena cava diameter, interdialytic weight gain, and pulmonary hypertension.
|
At baseline evaluation
|
|
Blood Pressure Variability and Pulmonary Hypertension
Prazo: At baseline evaluation
|
Relationship between intradialytic blood pressure variability and pulmonary hypertension parameters.
|
At baseline evaluation
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Cadeira de estudo: Gener Ismail, Professor, MD, PhD, Fundeni Clinical Institute
- Investigador principal: Georgiana N Olaru, MD, Institute for Cardiovascular Diseases C.C. Iliescu
- Cadeira de estudo: Ioan M Coman, Professor, MD, PhD, Institute for Cardiovascular Diseases C.C. Iliescu
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Vasculares
- Doenças cardiovasculares
- Processos Patológicos
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doença crônica
- Atributos da doença
- Doenças Respiratórias
- Doenças pulmonares
- Insuficiência renal
- Insuficiência Renal Crônica
- Hipertensão
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Insuficiência Renal Crônica
- Hipertensão Pulmonar
- Edema
Outros números de identificação do estudo
- 12798 (Outro identificador: Fundeni Clinical Institute - Ethics Committee)
- EU-PHASE-HD-01 (Outro identificador: Fundeni Clinical Institute - Adult Nephrology Department)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .